Estes JM - Search Results

1

Efficacy and toxicity of the novel chemotherapeutic agent KW-2170 in recurrent epithelial ovarian cancer.

Estes JM, Leath CA, Williams S, Modiano MR, Sawyer M, Cohn D, Straughn JM, Barnes MN, Alvarez RD. Estes JM, et al. Gynecol Oncol. 2006 Aug;102(2):338-42. doi: 10.1016/j.ygyno.2005.12.031. Epub 2006 Feb 20. Gynecol Oncol. 2006. PMID: 16487997 Clinical Trial.

2

Complications of indwelling venous access devices in patients with gynecologic malignancies.

Estes JM, Rocconi R, Straughn JM, Bhoola S, Leath CA, Alvarez RD, Kilgore LC, Huh WK. Estes JM, et al. Gynecol Oncol. 2003 Dec;91(3):591-5. doi: 10.1016/j.ygyno.2003.08.015. Gynecol Oncol. 2003. PMID: 14675682

3

The impact of aborted radical hysterectomy in patients with cervical carcinoma.

Leath CA 3rd, Straughn JM Jr, Estes JM, Kirby TO, Bhoola SM, Barnes MN 3rd, Kilgore LC, Alvarez RD. Leath CA 3rd, et al. Among authors: estes jm. Gynecol Oncol. 2004 Oct;95(1):204-7. doi: 10.1016/j.ygyno.2004.07.034. Gynecol Oncol. 2004. PMID: 15385133

4

Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer.

Bhoola SM, Coleman RL, Herzog T, Morris R, Bryant C, Estes JM, Alvarez RD. Bhoola SM, et al. Among authors: estes jm. Gynecol Oncol. 2004 Dec;95(3):564-9. doi: 10.1016/j.ygyno.2004.08.026. Gynecol Oncol. 2004. PMID: 15581964

5

Management strategies for stage IB2 cervical cancer: a cost-effectiveness analysis.

Rocconi RP, Estes JM, Leath CA 3rd, Kilgore LC, Huh WK, Straughn JM Jr. Rocconi RP, et al. Among authors: estes jm. Gynecol Oncol. 2005 May;97(2):387-94. doi: 10.1016/j.ygyno.2005.01.028. Gynecol Oncol. 2005. PMID: 15863134

6

Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A cost-effectiveness analysis.

Rocconi RP, Case AS, Straughn JM Jr, Estes JM, Partridge EE. Rocconi RP, et al. Among authors: estes jm. Cancer. 2006 Aug 1;107(3):536-43. doi: 10.1002/cncr.22045. Cancer. 2006. PMID: 16804928 Free article.

7

Bowel resection at the time of primary debulking for epithelial ovarian carcinoma: outcomes in patients treated with platinum and taxane-based chemotherapy.

Estes JM, Leath CA 3rd, Straughn JM Jr, Rocconi RP, Kirby TO, Huh WK, Barnes MN 3rd. Estes JM, et al. J Am Coll Surg. 2006 Oct;203(4):527-32. doi: 10.1016/j.jamcollsurg.2006.06.019. Epub 2006 Aug 17. J Am Coll Surg. 2006. PMID: 17000397

8

Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model.

Estes JM, Oliver PG, Straughn JM Jr, Zhou T, Wang W, Grizzle WE, Alvarez RD, Stockard CR, LoBuglio AF, Buchsbaum DJ. Estes JM, et al. Gynecol Oncol. 2007 May;105(2):291-8. doi: 10.1016/j.ygyno.2006.12.033. Epub 2007 Feb 15. Gynecol Oncol. 2007. PMID: 17303227

9

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its therapeutic potential in breast and gynecologic cancers.

Kendrick JE, Estes JM, Straughn JM Jr, Alvarez RD, Buchsbaum DJ. Kendrick JE, et al. Among authors: estes jm. Gynecol Oncol. 2007 Sep;106(3):614-21. doi: 10.1016/j.ygyno.2007.05.035. Epub 2007 Jun 29. Gynecol Oncol. 2007. PMID: 17602728 Review.

10

A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma.

Kimball KJ, Numnum TM, Kirby TO, Zamboni WC, Estes JM, Barnes MN, Matei DE, Koch KM, Alvarez RD. Kimball KJ, et al. Among authors: estes jm. Gynecol Oncol. 2008 Oct;111(1):95-101. doi: 10.1016/j.ygyno.2008.07.001. Epub 2008 Aug 8. Gynecol Oncol. 2008. PMID: 18692224 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

57 results

Search Page

Filters